Brief Fact Summary. The plaintiff, Sabel (“plaintiff”), sued the defendant, Mead Johnson & Co. pharmaceutical company (“defendant”), after the antidepressant drug Desyrel allegedly caused a priapism, requiring surgery and leaving him impotent.
Synopsis of Rule of Law. Special care must be taken in applying exceptions to the hearsay rule, especially when the risk of unfair prejudice substantially outweighs the relevance of the evidence. Moreover, in situations where an agency exception is to be used, a careful analysis of the alleged relationship between the parties must be performed.
Issue. Whether the tape of a meeting sponsored by the defendant was admissible?
Whether a letter written to the defendant by the Director of the Food and Drug Administration (“F.D.A.”) was admissible?
Whether notes made by an FDA employee of a telephone conversation with an employee of the defendant were admissible?
Held. No. With the exception of statements made by full time employees of the defendant, statements on the tape constituted inadmissible hearsay.
Yes. The letter qualified as a public record pursuant the public record exception to the hearsay rule under Federal Rule of Evidence (“F.R.E”), Rule 803(8)(c). The letter was a report consisting of findings that were the result of an investigation held pursuant to authority granted by law, and it was trustworthy, thus satisfying the two prong test for evidence to be admitted as a public record.
No. The notes were inadmissible hearsay. It is specifically in cases where accounts differ as to the substance of a hearsay statement that special care must be taken in applying exceptions. None apply in this case.
Factually based conclusions or opinions are not on that account excluded from the scope of Rule 803(8)(C).View Full Point of Law